¸»±â½ÅºÎÀü ȯÀÚ¿¡¼ Åõ¼®Ä¡·áÀÇ ½ÃÀÛÀÌ ¿°Áõ»óÅ ¹× ¸é¿ª¹ÝÀÀ¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ °üÇÑ ¿¬±¸
Effect of Initiating Dialysis on Inflammatory State and Immune Response in Patients with End-stage Renal Disease
´ëÇѽÅÀåÇÐȸÁö 2007³â 26±Ç 5È£ p.559 ~ p.566
ÀÌÀç¿ø(Lee Jae-Won) - °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÇý¿ø(Kim Hye-Won) - °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÚÀº¹ü(Park Eun-Bum) - °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ºÎâ¼ö(Boo Chang-Su) - °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
°í°Áö(Ko Gang-Jee) - °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¶»ó°æ(Jo Sang-Kyung) - °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Á¶¿ø¿ë(Cho Won-Yong) - °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÇü±Ô(Kim Hyung-Kyu) - °í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
¸ñ Àû: ¸¸¼º ¿°ÁõÀº ¸¸¼º½ÅºÎÀü ȯÀÚ¿¡¼ÀÇ ÈçÇÑ Æ¯Â¡À¸·Î, ¿µ¾ç°áÇÌ°ú Á×»ó°æÈÁõÀ» À¯¹ßÇÏ¿© ÀÌȯÀ²°ú »ç¸Á·üÀ» ³ô
ÀÌ´Â ÁÖµÈ ¿øÀÎÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. º» ¿¬±¸¿¡¼´Â Åõ¼® Àü ¸»±â½ÅºÎÀü ȯÀÚ¿¡¼ Åõ¼® Ä¡·áÀÇ ½ÃÀÛÀÌ ¿°Áõ ¹× ¿µ¾ç »óÅÂ,
±×¸®°í ¸é¿ª¹ÝÀÀ¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇØ ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.
¹æ ¹ý: ¸»±â½ÅºÎÀüÀ¸·Î °í·Á´ëÇб³ ¾È¾Ïº´¿ø¿¡¼ Ç÷¾×Åõ¼® (31¸í) ȤÀº º¹¸·Åõ¼® (26¸í) Ä¡·á¸¦ ½ÃÀÛÇÑ 57¸íÀÇ È¯ÀÚ
¸¦ ´ë»óÀ¸·Î ÇÏ¿´´Ù. °¢°¢ÀÇ È¯ÀÚ¿¡¼ Åõ¼®½ÃÀÛ Àü°ú Åõ¼®½ÃÀÛ 3°³¿ù ÈÄ ¿°Áõ¼º »çÀÌÅäÄ«ÀÎÀÎ tumor necrosis factor
(TNF)-¥á¿Í Ç׿°Áõ »çÀÌÅäÄ«ÀÎÀÎ interleukin (IL)-10,adiponectin °ªÀ» ÃøÁ¤ÇÏ¿´À¸¸ç, ¿°Áõ¼º Ç¥ÁöÀڷμ highly
sensitive C-reactive protein (hs-CRP) ¹× ¿µ¾ç»óÅÂÀÇ ÁöÇ¥·Î¼ Ç÷û ¾ËºÎ¹Î¿¡ ´ëÇؼµµ Á¶»çÇÏ¿´´Ù. ¿ÜºÎ Àڱؿ¡ ´ë
ÇÑ ¸é¿ª¹ÝÀÀ Á¤µµÀÇ º¯È¸¦ Æò°¡Çϱâ À§ÇØ °¢°¢ÀÇ È¯ÀÚ ÀüÇ÷¿¡ lipopolysaccharide (LPS)¸¦ ó¸®ÇÑ ÈÄ »çÀÌÅäÄ«ÀÎÀÇ º¯
È ¿©ºÎ¿¡ ´ëÇØ »ìÆì º¸¾Ò´Ù.
°á °ú: Åõ¼®Ä¡·á ½ÃÀÛ ÈÄ ¿äµ¶ ¹°ÁúÀÌ °¨¼ÒÇϸé¼, TNF-¥á°¡ °¨¼ÒÇÏ¿´À¸¸ç adiponectinÀº Áõ°¡ÇÏ¿´´Ù. ÀÌ·¯ÇÑ º¯È
¿¡ µ¿¹ÝÇÏ¿© highly sensitive C-reactive protein (hs-CRP)ÀÇ °¨¼Ò ¹× Ç÷û ¾ËºÎ¹ÎÀÇ Áõ°¡¸¦ º¸¿´´Ù. LPS ÀÚ±Ø
ÀüÈÄÀÇ TNF-¥á, IL-10ÀÇ Â÷ÀÌ´Â Åõ¼®½ÃÀÛ Àü¿¡ ºñÇÏ¿© Åõ¼®½ÃÀÛ 3°³¿ù ÈÄ¿¡ À¯ÀÇÇÏ°Ô Áõ°¡ÇÏ¿´´Ù. Ç÷¾×Åõ¼® ±º°ú º¹¸·
Åõ¼® ±º °£¿¡ adiponectinÀ» Á¦¿ÜÇÑ ÁöÇ¥µéÀÇ À¯ÀÇÇÑ Â÷À̴º¸ÀÌÁö ¾Ê¾ÒÀ¸¸ç, adiponectinÀº º¹¸·Åõ¼® ±º¿¡¼ ´õ ¸¹Àº
Áõ°¡¸¦ º¸¿´´Ù.
°á ·Ð: ¿¬±¸¿¡¼´Â ¸»±â½ÅºÎÀü ȯÀÚ¿¡¼ Åõ¼® Ä¡·áÀÇ ½ÃÀÛÀÌ ¿°Áõ»óŸ¦ °¨¼Ò½ÃÅ°°í ¿µ¾ç»óŸ¦ È£Àü½ÃÅ°¸ç, ÀûÀýÇÑ
¸é¿ª¹ÝÀÀÀ» ȸº¹½ÃÅ°´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ÀÌ·¯ÇÑ °á°ú´Â Åõ¼®Ä¡·á¸¦ ÅëÇØ ¿äµ¶ ¹°ÁúÀÌ ºÎºÐÀûÀ¸·Î ±³Á¤µÇ¸é¼ ³ªÅ¸³ª´Â
±àÁ¤Àû È¿°ú·Î ÆǴܵȴÙ. µû¶ó¼ ¸»±â½ÅºÎÀü ȯÀÚ¿¡¼ Åõ¼®Ä¡·á¸¦ ½ÃÀÛÇÏ´Â °ÍÀÌ ¿°Áõ ¹× ¿µ¾ç»óÅÂÀÇ °³¼±°ú ´õºÒ¾î ÀúÇÏ
µÈ ¸é¿ª±â´ÉÀ» ±³Á¤ÇÏ´Â µ¥ ÀÌÁ¡ÀÌ ÀÖ´Ù°í ÇÏ°Ú´Ù
Purpose : inflammation is a common feature in chronic kidney disease patients, and it could contribute to long-term morbidity and mortality related with malnutrition and atherosclerosis. In this study, we aimed to investigate the effect of initiating dialysis on inflammatory state, nutritional parameter, and immune response in end-stage renal disease (ESRD) patients.
Methods : 57 ESRD patients who initiated hemodialysis (HD, n=31) or continuous ambulatory peritoneal dialysis (CAPD, n=26) were enrolled. Pro-inflammatory cytokine, tumor necrosis factor (TNF)-¥á, and anti-inflammatory cytokines, interleukin (IL)-10 and adiponectin were measured before and 3 months after initiation of dialysis. Inflammatory marker, highly sensitive C-reactive protein (hs-CRP), and nutritional parameter, albumin, were also checked. Lipopolysaccharide (LPS)-stimulated production of TNF-¥á and IL-10 were measured for the evaluation of immune response by external stimuli.
Results : As uremia was reduced by initiating dialysis, serum level of TNF-¥á was decreased and adiponectin was increased. These changes were accompanied by the decrease of hs-CRP and the increase of serum albumin. LPS-stimulated cytokines production was increased after initiating dialysis. There differences in these parameters comparing HD and CAPD patients except more increase of serum adiponectin level in CAPD patients.
Conclusion : Our study demonstrated that initiation of dialysis results in decrease of inflammation, improvement of nutritional status, and restoration of proper immune responsiveness in ESRD patients. These results suggest that correction of uremic milieu through dialysis has beneficial effects. Therefore, initiation of dialysis might have the advantage of improving inflammatory and nutritional status, and correcting immune dysfunction in ESRD patients.
Å°¿öµå
Inflammation, Cytokines, Immunity, Dia
KMID :
0359920070260050559
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
There differences in these parameters comparing HD and CAPD patients except more increase of serum adiponectin level in CAPD patients; Ç÷¾×Åõ¼® ±º°ú º¹¸·Åõ¼® ±ºÀ¸·Î ³ª´©¾î ½ÃÇàÇÑ ºñ±³¿¡¼´Â Åõ¼®½ÃÀÛÀü°ú 3°³¿ù ÈÄ adiponectinÄ¡ÀÇ º¯È°¡ Ç÷¾×Åõ¼®È¯ÀÚ±ºº¸´Ù º¹¸·Åõ¼® ȯÀÚ±º¿¡¼ À¯ÀÇÇÏ°Ô ÄÇÀ½.